share_log

Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)

Benzinga ·  Dec 9 20:36
Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment